Analysts Set Target Price of $373.25 for Cencora, Inc. Shares

Shares of Cencora, Inc. (NYSE:COR) have received an average rating of “Moderate Buy” from analysts covering the stock, according to Marketbeat.com. The consensus target price set by these analysts stands at $373.25. This assessment comes from a total of thirteen analysts, with four rating the stock as a hold, eight issuing buy ratings, and one giving a strong buy rating.

Analysts have been actively revising their recommendations on Cencora. On December 8, Barclays initiated coverage with an “overweight” rating and set a price objective of $400.00. Following this, JPMorgan Chase & Co. increased its target from $344.00 to $417.00 in a report published on November 11. Similarly, Wells Fargo & Company adjusted its price target from $354.00 to $405.00 on the same day. Evercore ISI also set a target price of $400.00 with an “outperform” rating on November 6, while UBS Group raised their target from $380.00 to $415.00 on November 7.

Recent Financial Performance

Cencora’s most recent financial results, posted on November 5, revealed an earnings per share (EPS) of $3.84 for the quarter, surpassing analysts’ expectations of $3.79 by $0.05. The company reported a return on equity of 227.15% and a net margin of 0.48%. Revenue for the quarter reached $83.73 billion, exceeding analyst estimates of $83.36 billion. This represents a 5.9% increase compared to the same quarter last year, during which the firm earned $3.34 per share.

Looking ahead, Cencora has set its guidance for fiscal year 2026 at an EPS between $17.450 and $17.75. Analysts project that Cencora will achieve an average EPS of $15.37 for the current year.

Dividend Increase and Insider Activity

On December 1, Cencora announced an increase in its quarterly dividend, now set at $0.60 per share, up from $0.55. Shareholders of record on November 14 received this dividend, which translates to an annualized total of $2.40 and a yield of 0.7%. The company’s dividend payout ratio stands at 30.19%.

In other corporate news, Silvana Battaglia, Executive Vice President, sold 1,677 shares on December 19 at an average price of $345.00, totaling $578,565.00. After this transaction, Battaglia retained 18,796 shares, valued at approximately $6,484,620, reflecting an 8.19% decrease in ownership. Additionally, Robert P. Mauch, the Chief Executive Officer, sold 5,097 shares on October 20 for $1,665,699.60. Following this sale, Mauch holds 37,940 shares worth about $12,398,792, marking an 11.84% reduction in his holdings.

Over the last three months, insiders have sold a total of 20,317 shares valued at $7,009,260, with insiders currently owning 10.80% of the company’s stock.

Institutional Holdings

Institutional investors have been active in adjusting their positions in Cencora. Vestcor Inc. increased its stake by 0.5% during the third quarter, now holding 5,196 shares valued at $1,624,000. Cornerstone Wealth Group LLC raised its holdings by 1.3% to 2,383 shares worth $745,000. Other notable investors include Security Financial Services Inc., which grew its stake by 2.6%, and Vermillion & White Wealth Management Group LLC, which increased its holdings by 31.4%.

Approximately 97.52% of Cencora’s stock is owned by institutional investors and hedge funds, reflecting strong confidence in the company’s future performance.

Cencora, Inc. operates as a global healthcare services and pharmaceutical distribution company, providing comprehensive solutions across the pharmaceutical supply chain. Its core activities include drug distribution and specialty pharmacy services, alongside logistics and cold-chain management to support complex therapies. The company also offers a variety of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.